<DOC>
	<DOCNO>NCT00314704</DOCNO>
	<brief_summary>The purpose study compare efficacy dopamine norepinephrine , two commonly use vasopressor agent , treatment shock .</brief_summary>
	<brief_title>Dopamine Norepinephrine Shock Patients</brief_title>
	<detailed_description>Introduction : Vasopressor agent commonly use correct hypotension patient acute circulatory failure . Their variable alpha , beta , dopaminergic receptor stimulation , may result different hemodynamic metabolic effect . Several experimental human study indicate dopamine norepinephrine may different effect kidney , splanchnic region pituitary axis , implication finding assess . Hence , agent widely use , several consensus expert recommendation still recommend use agent 1,2 . An observational study report dopamine epinephrine may associate high mortality rate norepinephrine 3 . In addition , The result SOAP study indicate dopamine may associate high mortality rate norepinephrine , various uncontrolled factor may influence result . Therefore , address issue prospective , randomize , double blind study . We hypothesize agent similar effect survival . Design study : Prospective , randomize , double blind , multicenter . Patients : A total 1600 consecutive patient hypotension require administration vasopressor . Power calculation : Calculation base result SOAP study ( mortality 43 % dopamine 36 % norepinephrine ) , use two-sided analysis , significant p value 0.05 power 80 % , 765 patient need group . About 40 center recruit . Inclusion criterion : Mean arterial pressure le 70 mmHg systolic pressure le 100 mmHg persist despite adequate fluid loading ( example least 1000 mL crystalloid 500 ml colloid ) unless central venous pressure ( CVP ) pulmonary artery occlude pressure ( PAOP ) elevate ( e.g . CVP &gt; 12 mmHg PAOP &gt; 14 mmHg ) . Exclusions : - Serious arrhythmia rapid atrial fibrillation ( &gt; 160/min ) ventricular tachycardia . - Brain death . - Open label administration dopamine , norepinephrine , epinephrine phenylephrine 4hours . Consent : Patients randomize immediately , use seal envelope place near supply dopamine norepinephrine . If patient already treat one agent , randomization still take place provide within 4 hour period . Consent obtain patient enter study , possible , next kin soon possible start vasopressor therapy . Indeed , case , vasopressor therapy anyway start , either dopamine norepinephrine , 2 therapy currently equally valid 1st choice . As soon possible , next kin inform deferred consent obtain . If patient recovers , able consent , consent obtain . According local Ethical Committee , oral sign consent obtain . Protocol : Blood pressure goal : defined physician charge , accord unit 's recommendation Administration vasoactive drug : Double blind administration solution norepinephrine dopamine contain either vial syrinx accord ICU 's protocol ( see appendix I II vial syringe preparation ) . Each solution label randomly allocate number prepared nurse charge . The rate administration blind solution determine accord scale use estimate body weight . The recommended step increase decrease dos blind solution calculate equivalent 2 µg/kg.min dopamine 0.02 mcg/kg.min norepinephrine , investigator free use multiple increment case emergency . The maximal dose 2 agent 20 µg/kg.min dopamine 0.19 mcg/kg.min norepinephrine ( dose show similar effect mean arterial blood pressure 4 ) . If patient already treat open label vasopressor baseline , blind solution rapidly incremented , , possible , open label vasopressor agent decrease . If open label vasopressor consist dopamine agent fully wean introduction blind solution , open label dopamine replace open label norepinephrine infusion . When maximal dose blind solution achieve , open label perfusion norepinephrine add achieve desire blood pressure . Epinephrine vasopressin may use rescue therapy . Weaning vasopressor agent begin wean open label norepinephrine , follow wean blind solution . In case recurrence hypotension , blind solution resume first ( maximal dose 2 agent 20 µg/kg.min dopamine 0.19 mcg/kg.min norepinephrine ) need open label solution norepinephrine may add . Weaning vasopressor perform previously describe . Dobutamine , dopexamine , inhibitor phosphodiesterase III use , need , optimize cardiac output accord local practice . General therapeutic guideline : All therapy perform accord local guideline . The choice sedative agent , antibiotic , fluid , transfusion threshold , ventilatory mode , … . , leave attending physician . Likewise , administration agent like corticosteroid drotrecogin-alpha activate ( Xigris ) permit . Randomization : Randomization block participate ICU , use computer generate list allocate treatment A B , put seal envelope near drug supply . In ICU , seal envelope include treatment allocation five digit number available . The envelope open person responsible preparation dopamine norepinephrine solution . The random number treatment allocation write hidden book , available person responsible preparation dopamine norepinephrine solution . The doctor nurse kept blind treatment allocation . On patient ' chart rate administration dilution ( simple double ) solution write . Preparation solution : The solution dopamine norepinephrine prepared nurse charge patient . The five digit number ( allocated randomization ) write bag . See appendix I II detail regard preparation solution . Different concentration solution provide , choice concentration solution leave physician charge . Definition end shock period : Shock consider resolved investigational drug stop 12 hour . End-points : Primary end-point : 28 day survival Secondary end-points : ICU survival Hospital survival Severity organ dysfunction ICU ( SOFA score 5 ) Duration ICU stay , time spend vasopressor ( vasopressor free day ) , mechanical ventilation ( ventilator free day ) renal replacement ( renal replacement free day ) Efficacy dopamine correct hypotension Hemodynamic effect / concomitant use dobutamine inotropic agent Tolerance : arrhythmia ( incidence ventricular tachycardia , ventricular fibrillation atrial fibrillation ) , myocardial necrosis , skin necrosis , limb distal extremity ischemia . Occurrence secondary infection Impact target blood pressure outcome Measured variable : Data collect every 6 hour 48 hour every 8 hour day 5 Hemodynamic variable : Temperature , systolic diastolic arterial pressure , heart rate , central venous pressure . In patient equipped pulmonary artery catheter : pulmonary systolic diastolic pressure , pulmonary artery occlude pressure , cardiac output . In patient equipped device allow cardiac output measurement : cardiac output , extravascular lung water global end diastolic volume ( available ) Biologic variable : Arterial mixed-venous ( central venous pulmonary artery catheter available ) blood gas . Doses vasoactive agent : trial drug , open label vasoactive drug ( norepinephrine , epinephrine , vasopressin , dobutamine ) Data collect daily first 7 day day 14 , 21 28 : Hemoglobin , platelet , white blood cell count , APTT , glucose level , urea , creatinine , sodium , potassium , GOT , GPT , CPK , LDH , PAL , bilirubin , amylase , lipase , CRP , lactate , PCT ( available ) Respiratory condition ( type ventilation condition ) Fluid balance ( In/Out ) Microbiological data antibiotic therapy Calculation APACHE II 6 SAPS II score admission inclusion study calculation SOFA score daily first 7 day day 14 , 21 28 . Statistics : A/ Interim analysis : Sequential analysis every 100 include patient , allow premature stop study case significant difference 28-day survival two treatment , futility B/ Final analysis : Intention treat analysis Kaplan-Meier curve ( log rank test ) use assess ICU 28-day survival well duration vasopressor therapy ( label open label drug ) ICU stay . Analysis variance follow t-test Bonferroni correction continuous variable chi square categorial variable . Significance p &lt; 0.05 . C/ Additional subgroup analysis : - Analysis subgroup schedule septic shock , cardiogenic shock , type shock . - Per protocol analysis , take account patient exclude arrhythmias . - Subgroup analysis accord dose vasoactive agent ( trial drug trial plus open label drug ) References : 1 . Task Force American College Critical Care Medicine , Society Critical Care Medicine . Practice parameter hemodynamic support sepsis adult patient sepsis . Crit Care Med 1999 ; 27:639-660 . 2 . Vincent J-L. Hemodynamic support septic shock . Intensive Care Med 2001 ; 27 : S80-S92 3 . Martin C , Viviand X , Leone M , Thirion X . Effect norepinephrine outcome septic shock . Crit Care Med 2000 ; 28:2758-2765 . 4 . Marik PE , Mohedin M. The contrasting effect dopamine norepinephrine systemic splanchnic oxygen utilization hyperdynamic sepsis . JAMA 1994 ; 272:1354-1357 . 5 . Vincent JL , Moreno J , Takala J , Willatts S , De Mendonça A , Bruining H , et al . The SOFA ( Sepsis-related Organ Failure Assessment ) score describe organ dysfunction/failure . Intensive Care Med 2000 ; 22:707-710 . 6 . Knaus WA , Draper EA , Wagner DP , Zimmerman JE . APACHE II : severity disease classification system . Crit Care Med 1985 ; 13:818-829 .</detailed_description>
	<mesh_term>Shock</mesh_term>
	<mesh_term>Norepinephrine</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<mesh_term>Dopamine Agents</mesh_term>
	<criteria>Mean arterial pressure le 70 mmHg systolic pressure le 100 mmHg persist despite adequate fluid loading ( example least 1000 mL crystalloid 500 ml colloid ) unless central venous pressure ( CVP ) pulmonary artery occlude pressure ( PAOP ) elevate ( e.g . CVP &gt; 12 mmHg PAOP &gt; 14 mmHg ) . Serious arrhythmia rapid atrial fibrillation ( &gt; 160/min ) ventricular tachycardia . Brain death . Open label administration dopamine , norepinephrine , epinephrine phenylephrine 4hours .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2006</verification_date>
	<keyword>shock</keyword>
	<keyword>hypotension</keyword>
	<keyword>circulatory failure</keyword>
	<keyword>septic shock</keyword>
	<keyword>cardiogenic shock</keyword>
</DOC>